A New Shot for Very High Triglycerides: What Olezarsen's FDA Approval Means for Patients
Almost every cholesterol panel I read lists four numbers, and the one patients ask about least is often triglycerides. Most people with a mildly high triglyceride level do fine with diet and time. A smaller group runs numbers so high that the fat in their blood becomes a direct threat to the pancreas. For that group, we’ve had thin options for years. In June 2026 the FDA approved olezarsen (brand name Tryngolza) as the first medicine cleared to lower triglycerides and cut the risk of acute pancreatitis in adults with severe hypertriglyceridemia. I want to walk you through what triglycerides are, why the very high ones are dangerous, how this new drug works, and who should be thinking about it.
What triglycerides are, and when they stop being harmless
Triglycerides are the storage form of fat that circulates in your blood. You make them from the food you eat, especially refined carbohydrates, alcohol, and sugary drinks, and your body draws on them for energy between meals. A normal fasting level sits under 150 mg/dL. Plenty of my patients run in the 150 to 400 range, usually tied to weight, blood sugar, alcohol, or genetics, and for them the conversation is about lifestyle and treating the underlying cause.
The picture changes once triglycerides climb past 500 mg/dL, and it changes sharply above 1,000. At those levels the blood can carry so much fat that it takes on a milky look, and the excess starts to injure the pancreas, the organ tucked behind your stomach that makes digestive enzymes and insulin. When fat overwhelms it, the pancreas can inflame violently. That’s acute pancreatitis, and it’s one of the more painful, dangerous problems I see. A severe attack can land someone in the hospital for days, cause lasting damage to the gland, and in the worst cases turn life-threatening. People who’ve had one attack live with the fear of the next.
Doctors call this range severe hypertriglyceridemia, which just means triglycerides of 500 mg/dL or higher. The goal in these patients isn’t a prettier lab sheet. It’s keeping them out of the hospital.
Why the tools we’ve had haven’t been enough
For decades the plan for very high triglycerides has leaned on lifestyle plus a short list of medicines. We push hard on cutting alcohol, cutting refined carbs and sugar, losing weight, and controlling diabetes, because all of those raise triglycerides. On the drug side we’ve reached for fibrates, prescription fish oil at high doses, and sometimes niacin. These help, and for many patients they’re enough to pull a number back from the edge.
The problem is the patients they don’t help. Some people have a genetic wiring that keeps triglycerides sky-high no matter how disciplined they are with food and how many fibrate capsules they take. I’ve had patients doing everything right whose levels still sat above 1,000, and I had little left to offer them beyond repeating advice they were already following. Fibrates and fish oil also tend to move triglycerides modestly, not dramatically, so a patient starting at 2,000 mg/dL can do the whole regimen and still land in dangerous territory. That gap, the patients whose triglycerides won’t come down with what we already have, is the gap olezarsen was built to fill.
What olezarsen does differently
To understand this drug, you need one protein: apolipoprotein C-III, which I’ll call apoC-III. Your liver makes it, and its job is to slow down the clearance of triglycerides from your blood. Think of apoC-III as a brake on the system that normally sweeps fat out of circulation. Some people make too much of it, so the brake stays on and triglycerides pile up.
Olezarsen is what we call an antisense drug. Instead of blocking the apoC-III protein after it’s made, it works one step earlier, inside the liver, by interfering with the genetic message the liver uses to build apoC-III in the first place. Less message, less protein, less brake. With the brake eased off, your body clears triglycerides out of the blood the way it’s supposed to. The drug is built with a sugar tag that steers it almost entirely to liver cells, which is where the action needs to happen, so it does its work without scattering through the rest of the body.
The practical part patients like: it’s a shot you give yourself once a month with an autoinjector, similar in feel to the pen devices used for some diabetes and cholesterol drugs. Once monthly, not daily.
The trials that got it approved
The approval rests on two Phase 3 studies called CORE and CORE2, which together enrolled just over a thousand adults whose triglycerides were 500 mg/dL or higher. Patients were assigned to give themselves olezarsen at one of two doses, 50 mg or 80 mg, or a placebo, once a month for a year.
The triglyceride numbers were strong. Patients on the drug saw their fasting triglycerides fall by more than 72 percent at the six-month mark, and the drop held through a full year. For someone starting at 1,500 mg/dL, a cut of that size is the difference between the danger zone and something close to normal.
The number I care about most, though, is what happened to pancreatitis. Across both trials, olezarsen reduced acute pancreatitis events by roughly 85 percent compared with placebo. That’s the whole point of treating these patients. We lower the fat in the blood so the pancreas stops getting attacked. Seeing the attacks themselves drop, not the lab value, is what makes this approval meaningful for the people I’d prescribe it to. The side-effect profile in the studies was manageable, with injection-site reactions being the most common complaint, the kind of thing you’d expect from any monthly shot.
Who I think this is for
The right candidate is an adult whose triglycerides sit at 500 mg/dL or above despite doing the groundwork: cleaning up diet and alcohol, treating diabetes, taking a fibrate or fish oil if appropriate. If your number keeps climbing past 500 and especially past 1,000, and you’ve either had a bout of pancreatitis or your doctor is worried you’re heading for one, this is a real conversation to have.
It fits especially well for the patients I mentioned earlier, the ones with a stubborn genetic component whose triglycerides never fully responded to the older drugs. For them, olezarsen isn’t one more incremental option. It’s a different mechanism that reaches a problem the older medicines couldn’t.
I want to be honest about a few limits.
This is for very high triglycerides, not routine ones. If your triglycerides run 180 or 250, this drug isn’t for you, and reaching for it would be the wrong move. Your path is weight, diet, alcohol, blood sugar, and often a statin aimed at your overall heart risk. Olezarsen was studied and approved for the severe end of the spectrum, where pancreatitis is the danger.
Triglycerides are a different target than LDL. A lot of patients blur triglycerides together with the LDL cholesterol number that drives heart-attack risk. They’re related but separate problems. Lowering triglycerides with this drug is about protecting the pancreas. It doesn’t replace the work of managing LDL, which I cover in my guide to LDL cholesterol. Some patients need attention on both fronts.
Cost and access will take time to settle. Tryngolza is brand-new for this use, and a monthly branded injection carries a real price. Early on, getting it covered will likely mean documenting that you’ve tried and haven’t responded to the standard steps first. Fibrates and fish oil are cheap, so insurers will want to see them tried before they approve a new specialty drug.
What to do if your triglycerides have been high
If your triglycerides run in the normal-to-moderately-high range, nothing here changes your plan. Keep working on the fundamentals. Cutting back on alcohol and sugary drinks, losing a modest amount of weight, and getting blood sugar under control move triglycerides more than most people expect. A Mediterranean-style pattern of eating helps here, and I laid out how I think about that in my article on the Mediterranean diet. If your high triglycerides travel with a big waistline, high blood sugar, and high blood pressure, you may be dealing with the cluster I describe in my piece on metabolic syndrome, where treating the whole picture beats chasing any single number.
If your triglycerides have been running above 500 despite real effort, bring olezarsen up at your next visit. Good questions to ask: Have we found and treated everything driving my triglycerides up, from alcohol to blood sugar to medications? Have I given fibrates or high-dose fish oil a fair trial? Am I at the level where pancreatitis is a genuine risk? If so, would this new drug fit? For patients who are also carrying extra weight and high blood sugar, a GLP-1 medication sometimes addresses several of these problems at once, and that’s worth folding into the same conversation.
My take
Severe hypertriglyceridemia has been a frustrating corner of my practice. The patients are often young, often scared after a pancreatitis attack, and until now I’ve had a short menu that didn’t work for the ones who needed it most. Olezarsen changes that. A monthly shot that drops triglycerides by more than 70 percent and cuts pancreatitis attacks by roughly 85 percent is a real answer for a group that’s been stuck.
It won’t touch the far larger number of people with mildly elevated triglycerides, and it shouldn’t. For them the work stays the same: diet, weight, alcohol, blood sugar. For the smaller group living at the dangerous end, though, this is the first medicine built to protect the pancreas directly. I expect to be reaching for it, and I’m glad it’s finally here.